Table 2.
Previous treatment and transplant details
| Treatment details | Number (%) |
|---|---|
| Induction chemotherapy | |
| CHOP | 57 (88) |
| CHOP and etoposide | 2 (3) |
| Others anthracycline-containing combination chemotherapies | 6 (9) |
| Response after induction chemotherapy | |
| CR | 12 (18) |
| PR | 41 (64) |
| Primary refractorinessa | 12 (18) |
| Second-line chemotherapy | 46 (71) |
| ESHAP or DHAP | 27 (42) |
| Other platinum-containing regimen | 4 (6) |
| Others | 15 (23) |
| Number of pre-transplant regimens | |
| 1 | 18 (28) |
| 2 | 42 (65) |
| >2 | 5 (7) |
| Disease status at autoHSCT | |
| CR | 36 (55) |
| PR | 29 (45) |
| Autologous graft source | |
| Mobilized peripheral blood | 62 (95) |
| Bone marrow | 3 (5) |
| The number of infused CD34 positive cells ×106/kg | |
| Median | 5.6 |
| Range | 1.6–22.8 |
| Conditioning regimen | |
| BEAM | 38 (58) |
| CBV | 18 (28) |
| CyTBI | 3 (5) |
| Others | 6 (9) |
CR complete response, PR partial response
aLess than PR